Skip to main content

Global Autoinjector Market by Type, Treatment, Drug Descriptions, Analysis And Synthesis

Global Autoinjector Market is currently dominated by many market players. The key players in the market are engaged in new product launches and strategic collaborations to strengthen their market position. For instance, in June 2018, AbbVie, Inc. and Eisai Co., Ltd. launched HUMIRA pen, an autoinjector formulation for fully human anti-TNF- α monoclonal antibody.
Global Autoinjectors Market is expected to register a CAGR of 17.42% to reach USD 79,741 Million by 2024.
Some of the key players in the global autoinjector market are AbbVie, Inc., Eli Lily and Company, Ypsomed, Amgen, Inc., Becton, Dickinson and Company, Owen Mumford, Consort Medical, Unilife Corporation, SHL Group (Scandinavian Health Limited), Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., Antares Pharma, Novartis International AG, and Bayer AG.
Avail Sample Copy for this Report Before Purchase: https://www.marketresearchfuture.com/sample_request/6311
The global autoinjectors market has been segmented into type, therapy, and distribution channel.
The market, on the basis of type, has been segmented into disposable autoinjectors and reusable autoinjectors.
The market, by therapy, has been segmented into rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and others.
The market, by distribution channel, has been segmented into retail pharmacies, hospital pharmacies, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The autoinjectors market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European autoinjectors market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The autoinjectors market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The autoinjectors market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Analysis
The market in the Americas is expected to dominate the global autoinjectors market during the forecast period owing to the presence of a well-established healthcare system, increasing healthcare expenditure, and growing prevalence of chronic diseases such as diabetes and cancer. According to the National Diabetes Statistics Report 2017, an estimated 30.3 million people of all ages had diabetes in the US in 2015.
The European market is expected to be the second-largest due to government funding and support of the healthcare sector coupled with the rising prevalence of various chronic diseases.
Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the assessment period owing to growing disposable income, increasing incidence of several diseases, and favorable government initiatives for healthcare facilities. The market in the Middle East and Africa is likely to account for the smallest share of the global autoinjectors market.
The market growth in this region can be attributed to the growing expenditure for the healthcare sector and developing healthcare infrastructure.
Browse Complete 108  Pages Premium Research Report Enabled with 121 Respective Tables and Figures athttps://www.marketresearchfuture.com/reports/autoinjectors-market-6311  
For instance, in September 2016, Bayer AG received the US Food and Drug Administration (FDA) approval for its electronic autoinjector BETACONNECT for the multiple sclerosis therapy. In addition, in May 2017, the company announced the approval by the US Food and Drug Administration (FDA) for myBETAapp and the BETACONNECT Navigator. With this software, people using the electronic BETACONNECT autoinjector to administer BETASERON (interferon beta-1b) can use the Bluetooth technology to connect their current autoinjector to the new myBETAapp on their mobile device or computer.
Moreover, a favorable reimbursement scenario and the availability of generic versions of autoinjectors boost the growth of the market. However, stringent government regulations for product approval and growing preference for alternative drug delivery modes such as nasal sprays may hamper the market growth during the assessment period.
Global Autoinjectors Market, by Region
  • Americas
    • North America
      • US
      • Canada
    • Latin America
  • Europe
    • Western Europe
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Rest of Western Europe
    • Eastern Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Rest of Asia-Pacific
  • Middle East & Africa
    • Middle East
    • Africa
About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar, Pune
+1 646 845 9312

Comments

Popular posts from this blog

Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Growth Drivers, Restraints and Opportunities, Forecast To 2025

Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Size Research Report: Information by Treatment (Drug Class (Mitogen-Activated Protein Kinases (MAPK) Inhibitors, Tyrosine Kinase Inhibitors, Autotaxin Inhibitors, Others), Oxygen Therapy, Lung Transplant, Others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025 Global  Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Size  Insights 2020 provides a unique tool for evaluating the Market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly-evolving and competitive environment, up-to-date Marketing information is essential to monitor performance and make critical decisions for growth and profitability. Some of the key players operating for the global market analysis are  Boehringer Ingelheim GMBH, Biogen, Novartis AG, Medicinova, Inc., Bristol-Myers Squibb Company, Galapagos NV, F. Hoffmann-La Roche AG, Fibro

Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Regional Analysis, Competitive Landscape Forecast to 2023

Idiopathic Pulmonary Fibrosis Treatment is a life-threatening condition of the lungs in which tissues becomes thickened, stiff, and scarred over a long period. The IPF treatment market is driven by various factors such as growing demand for minimally invasive procedures to diagnose and treat different chronic diseases, increasing geriatric population, along with the rising prevalence rates of IPF and other fibrotic diseases. Market Overview The high cost of surgery and the unavailability of proper treatment options are expected to curb the growth of the IPF treatment. The Global  Idiopathic Pulmonary Fibrosis Treatment Market  is expected to register a  CAGR of 12.3%  during the forecast period of 2019 to 2025, with a market value of USD 2,237 million in 2018. The global IPF treatment market is currently dominated by numerous market players. The key players are involved in new product launches and strategic collaborations to strengthen its market position. For instance, in Sept

Chatbots in Healthcare Market Research Report by Top Industry Vendors and Applications Scenario till 2023

Chatbots in Healthcare Market Overview Healthcare chatbots are programs which assist patients with queries. This reduces the burden on the clinical staff and lets them focus on their jobs. Automation of various workflow processes in the healthcare sector is likely to propel the demand for these virtual assistants. The global Chatbots in Healthcare Market is expected to touch USD 316.85 million by 2023 at 21.10% CAGR over the forecast period (2018-2023), as per Market Research Future (MRFR). It stood at USD 100.46 million in 2017. Rise of chronic diseases coupled with lack of medical experts to handle queries are main drivers of the market. For instance, cancer patients used chatbots to gain rapid assistance regarding medication and their adverse effects.  The  Chatbots in Healthcare Market   Free Growth Sample will provide valuable insight with an emphasis on the global market including some of the  major players  such As,  Sensely, Inc. (U.S.), Your.MD (U.K.), Buoy Healt